Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03694821 · ClinicalTrials.gov registry record · Phase 4
Knee Injection RCT
A Phase 4 study, sponsored by UConn Health.
- Terminated
- Registry status
- Phase 4
- Development phase
- 18
- Enrollment target
NCT03694821: Clinical Trial Phase 4 study, sponsored by UConn Health.
NCT03694821 is a Phase 4 study that was terminated before completion, run by UConn Health. The registered enrollment target is 18 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03694821, a Phase 4 study, was terminated before completion, sponsored by UConn Health.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 18 participants
- Enrollment target
Study Summary
Hypothesis: Ketorolac injection is a cost-effective adjunct in the nonoperative treatment of knee osteoarthritis (OA) compared to steroids and viscosupplementation. Aims/objectives: The objective of this randomized, controlled, double-blinded, prospective study is to assess the efficacy and cost-effectiveness of knee injection with ketorolac in the nonsurgical management of symptomatic OA compared to injections with corticosteroids and viscosupplements.
Primary Outcome
average knee pain between 0 (no pain) and 10 (worst pain) 3 months following injection
Interventions
- DRUG Ketorolac Tromethamine Injection
- DRUG Methylprednisolone Acetate Injection
- DRUG Hylan G-F 20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-07-05 |
| Est. Completion | 2019-07-16 |
| Phase | Phase 4 |
Why NCT03694821 stopped before completion
NCT03694821 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Ketorolac Tromethamine Injection is the first listed.
NCT03694821 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03694821 about?
NCT03694821 is a clinical study titled "Knee Injection RCT". Hypothesis: Ketorolac injection is a cost-effective adjunct in the nonoperative treatment of knee osteoarthritis (OA) compared to steroids and viscosupplementation. Aims/objectives: The objective of this randomized, controlled, double-blinded, prospective study is to assess the efficacy and cost-ef...
What is the current status of trial NCT03694821?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 18 participants. The study started on 2018-07-05. Estimated completion is 2019-07-16.
What interventions are being tested in trial NCT03694821?
The interventions under investigation include: Ketorolac Tromethamine Injection (DRUG), Methylprednisolone Acetate Injection (DRUG), Hylan G-F 20 (DRUG).
Who is sponsoring clinical trial NCT03694821?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03694821's enrollment target sits among peer trials
18 1842nd of 2000 higher than 147 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI